COVID-19 Vaccine Supply Challenges Reach The Litigation Stage
A contract manufacturing deal has soured as Inovio claims VXGI is breaching a supply agreement that requires it to transfer manufacturing technology to other companies if it cannot produce enough of Inovio's COVID-19 vaccine candidate.
You may also be interested in...
Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?
An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'.
FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.